MAP2K5 and lung cancer: Besides definition of patients that may benefit from targeting the MEK5/ERK5 pathway, efforts directed at developing clinical stage drugs that specifically target this pathway should offer novel therapeutic opportunities to fight lung cancer and potentially other tumors in which this pathway plays a pathophysiological role.